Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis
- PMID: 18490457
- PMCID: PMC2493235
- DOI: 10.1128/IAI.00005-08
Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis
Abstract
Neisseria meningitidis LpxL1 lipopolysaccharide (LPS) bearing penta-acylated lipid A is considered a promising adjuvant candidate for inclusion in future N. meningitidis vaccines, as it elicits a markedly reduced endotoxic response in human macrophages relative to that in wild-type (hexa-acylated) LPS, while it is an equally effective adjuvant in mice. As dendritic cells (DC) and Toll-like receptors (TLR) are regarded as central mediators in the initiation of an immune response, here we evaluated the ability of LpxL1 LPS to mature and to activate human DC and examined its TLR4-/MD-2-activating properties. Unexpectedly, purified LpxL1 LPS displayed minimal human DC-stimulating properties compared to wild-type LPS. Although whole bacteria induced DC maturation and activation irrespective of their type of LPS, the LpxL1 mutant failed to activate the human recombinant TLR4/MD-2 complex expressed in HeLa cells. Similarly, purified LpxL1 LPS was unable to activate human TLR4/MD-2 and it even acted as an antagonist of wild-type LPS. Both wild-type and LpxL1 LPSs activated the murine TLR4/MD-2 complex, consistent with their abilities to induce maturation and activation of murine DC. Assays with cells transfected with different combinations of human and murine TLR4 and MD-2 indicated that TLR4 was a more-major determinant of the LPS response than MD-2. The species-specific activation of the TLR4/MD-2 complex by LpxL1 LPS may have an impact on the use of LpxL1 LPS as an adjuvant and the use of murine immunization models in human meningococcal vaccine development.
Figures






Similar articles
-
The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.Infect Immun. 2010 Jul;78(7):3177-86. doi: 10.1128/IAI.01311-09. Epub 2010 May 3. Infect Immun. 2010. PMID: 20439476 Free PMC article.
-
Recognition of lipid A variants by the TLR4-MD-2 receptor complex.Front Cell Infect Microbiol. 2013 Feb 12;3:3. doi: 10.3389/fcimb.2013.00003. eCollection 2013. Front Cell Infect Microbiol. 2013. PMID: 23408095 Free PMC article. Review.
-
Neisseria meningitidis lipid A mutant LPSs function as LPS antagonists in humans by inhibiting TLR 4-dependent cytokine production.Innate Immun. 2011 Dec;17(6):517-25. doi: 10.1177/1753425910383999. Epub 2010 Nov 18. Innate Immun. 2011. PMID: 21088052
-
Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.Clin Vaccine Immunol. 2010 Apr;17(4):487-95. doi: 10.1128/CVI.00423-09. Epub 2010 Jan 27. Clin Vaccine Immunol. 2010. PMID: 20107001 Free PMC article.
-
The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex.Mol Immunol. 2015 Feb;63(2):134-42. doi: 10.1016/j.molimm.2014.06.034. Epub 2014 Jul 15. Mol Immunol. 2015. PMID: 25037631 Review.
Cited by
-
The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.Infect Immun. 2010 Jul;78(7):3177-86. doi: 10.1128/IAI.01311-09. Epub 2010 May 3. Infect Immun. 2010. PMID: 20439476 Free PMC article.
-
Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide.Sci Rep. 2016 Nov 14;6:36575. doi: 10.1038/srep36575. Sci Rep. 2016. PMID: 27841285 Free PMC article.
-
Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans.Hum Vaccin Immunother. 2021 Feb 1;17(2):601-613. doi: 10.1080/21645515.2020.1780092. Epub 2020 Jul 20. Hum Vaccin Immunother. 2021. PMID: 32687736 Free PMC article. Review.
-
Recognition of lipid A variants by the TLR4-MD-2 receptor complex.Front Cell Infect Microbiol. 2013 Feb 12;3:3. doi: 10.3389/fcimb.2013.00003. eCollection 2013. Front Cell Infect Microbiol. 2013. PMID: 23408095 Free PMC article. Review.
-
Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: implications for vaccine development.Clin Vaccine Immunol. 2012 May;19(5):711-22. doi: 10.1128/CVI.05683-11. Epub 2012 Mar 21. Clin Vaccine Immunol. 2012. PMID: 22441387 Free PMC article.
References
-
- Akashi, S., Y. Nagai, H. Ogata, M. Oikawa, K. Fukase, S. Kusumoto, K. Kawasaki, M. Nishijima, S. Hayashi, M. Kimoto, and K. Miyake. 2001. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition. Int. Immunol. 131595-1599. - PubMed
-
- Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392245-252. - PubMed
-
- Cartwright, K., R. Morris, H. Rumke, A. Fox, R. Borrow, N. Begg, P. Richmond, and J. Poolman. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 172612-2619. - PubMed
-
- de Kleijn, E. D., R. de Groot, J. Labadie, A. B. Lafeber, G. van den Dobbelsteen, L. van Alphen, H. van Dijken, B. Kuipers, G. W. van Omme, M. Wala, R. Juttmann, and H. C. Rumke. 2000. Immunogenicity and safety of a hexavalent meningococcal outer membrane vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 181456-1466. - PubMed
-
- Dixon, G. L., P. J. Newton, B. M. Chain, D. Katz, S. R. Andersen, S. Wong, P. van der Ley, N. Klein, and R. E. Callard. 2001. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria. Infect. Immun. 694351-4357. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials